Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietBG ControlIssue 682

Skipping Breakfast May Increase Risk of Type 2 Diabetes for Women

Glucose total AUC was greater in the no-breakfast group compared with the breakfast group....
Advertisement

During a press conference at ENDO 2013, Dr. Elizabeth A. Thomas from the University of Colorado School of Medicine, said skipping breakfast could have adverse cardiometabolic effects in obese women, including an increased risk for type 2 diabetes.

Thomas and colleagues conducted a randomized, crossover trial of 9 obese women aged 29.2 years (BMI 31.4 kg/m2) during 2 study days, roughly 1 month apart during the follicular phase of their menstrual cycle. They were randomly assigned to either breakfast containing 25% of daily energy intake or no breakfast at all. Their lunch contained 35% of their daily energy intake, Thomas said.

According to data, pre-lunch insulin levels did not differ between groups. However, glucose total AUC was greater in the no-breakfast group compared with the breakfast group (20,775 mg/dL vs. 18,126 mg/dL×180 minutes; P=.004).

Further, pre-lunch free fatty acids appeared higher among patients in the no-breakfast group compared with the breakfast group (705 mEq/L vs. 25,692 mEq/L×180 minutes; P=.0002).

Additional study data indicate the incremental AUC for free fatty acids was also greater among patients in the no-breakfast group compared with the breakfast group (–92980 vs. –26008 mEq/L ×180 minutes; P<.001). This suggests pre-lunch free fatty acids did not promote the increased AUC, according to Thomas.

Pre-lunch triglycerides were also lower in the no-breakfast group. However, the AUC did not vary between groups, suggesting that a pre-lunch triglyceride level drove the response, Thomas said.

"In obese women, skipping breakfast results in acute relative insulin resistance and elevated levels of free fatty acids," Thomas said. "It's possible that insulin resistance over time may predispose patients to further metabolic derangements and possibly progression to type 2 diabetes."

Practice 

  • Although the study was informative, other details need to be examined such as their other eating habits, which may be playing a role.

Presented at: The Endocrine Society Annual Meeting and Expo; June 15-18, 2013; San Francisco 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 21 June, 2013 and appeared in  DietBG ControlIssue 682

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015
Second Tuberculosis Vaccine Treatment for Type 1 Diabetes Underway
Posted June 19, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
Tracy Breen, MD

Category: General Diabetes
Credits: 1.0